Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 28;9(7):e1509.
doi: 10.1097/TXD.0000000000001509. eCollection 2023 Jul.

Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report

Weerawaroon Mavichak  1 , Suthanit Laowalert  2 , Touch Ativitavas  3 , Daraporn Rungprai  4   5
Affiliations

Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report

Weerawaroon Mavichak et al. Transplant Direct. .
No abstract available

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
CT scan of the patient’s liver masses (arrow). (A) Before treatment. (B) Six mo after treatment. (C) Four y after treatment.
FIGURE 2.
FIGURE 2.
The patient’s serum creatinine level from the beginning of treatment in 2018–2022.
See this image and copyright information in PMC

References

    1. Rouprêt M, Babjuk M, Burger M, et al. . EAU Guidelines on upper urinary tract urothelial carcinoma. European Association of Urology. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidel.... Accessed December 3, 2022. - PubMed
    1. Dang E, Vallée A, Lepage-Seydoux C, et al. . Clinical benefit of pembrolizumab in advanced urothelial cancer patients in real-life setting: an efficacy and safety monocentric study. Curr Oncol. 2022;29:945–955. - PMC - PubMed
    1. Balar AV, Castellano D, O’Donnell PH, et al. . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–1492. - PubMed
    1. Seethapathy H, Herrmann SM, Sise ME. Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management. Kidney Med. 2021;3:1074–1081. - PMC - PubMed
    1. Murakami N, Mulvaney P, Danesh M, et al. .; Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100:196–205. - PMC - PubMed